CMS Ends TAVR’s Mandatory Two-Operator Rule

TAVR national coverage determinationWhat to know

30-second read

For Cardiology · Cardiothoracic Surgery

Who

Cardiac surgery programs already offering, or weighing whether to start, TAVR for Medicare patients with symptomatic severe aortic stenosis.

What changed

CMS dropped the mandatory two-operator rule (a cardiologist and a surgeon jointly performing every case) and eliminated hospital procedural-volume minimums for existing programs.

What it pays for

Medicare coverage of TAVR for symptomatic severe AS no longer requires enrollment in a specific national outcomes registry as a coverage condition.

Key consideration

On-site cardiac surgery and ICU capability are still required — this is relief for existing heart programs, not an opening for hospitals without cardiac surgery.

Effective date

Finalized 10 September 2026 per the most consistent trade-press accounts (CMS's own decision memo was not independently confirmable from this newsroom).

Practice impactReview your program's operator model

Existing cardiac-surgery heart programs gain flexibility — a single operator may now do TAVR, volume minimums are gone — but on-site cardiac surgery stays required. Worth a staffing and reporting review, not an urgent change.

Read the full physician analysis

Full analysis · 9 min readSTS, ACC & SCAI coverage of CMS's TAVR decision memo · CMS NCD 20.32, September 2026

CMS finalized an updated national coverage determination for transcatheter aortic valve replacement (TAVR) in mid-September 2026 — 10 September, per the earliest and most consistent professional-society accounts — after a nine-month reconsideration requested by Edwards Lifesciences. The most consequential change for practicing physicians: a single qualified operator, either an interventional cardiologist or a cardiac surgeon, can now perform TAVR in a Medicare patient with symptomatic severe aortic stenosis, ending the requirement that one of each specialty be scrubbed in together for every case. CMS also eliminated hospital procedural-volume minimums for existing programs and replaced a mandatory national-registry enrollment requirement with a more general quality-improvement mandate. What did not change, according to multiple independent society accounts: hospitals still need on-site cardiac surgery and ICU capability to offer TAVR at all. This is relief for established heart programs, not an opening for hospitals without cardiac surgery to start one.

The operator rule that just loosened

The prior NCD, last updated in 2019, defined the TAVR heart team as including a cardiac surgeon and an interventional cardiologist who each independently evaluated a patient's suitability for surgical valve replacement, TAVR, or medical therapy — and it went further, requiring that the heart team's surgeon and cardiologist jointly participate in the intra-operative technical aspects of the procedure itself. That was a literal staffing requirement, not a consult. The updated NCD keeps the heart-team concept — at minimum one cardiologist and one surgeon as named team members, alongside advanced practice providers and nurses — but no longer requires both specialties to be the ones physically performing the case. A single qualified operator, of either specialty, is now sufficient for coverage; the heart team retains the discretion to use two operators when it judges a particular case warrants it.

What stays required

The change most likely to be misread is the one about which hospitals now qualify. Multiple independent professional-society accounts of the final decision describe the NCD as maintaining hospitals' on-site cardiac surgery capability and access to critical-care resources as a condition of TAVR coverage. What's gone is the specific minimum annual procedure-volume threshold institutions previously had to clear — both at the hospital level and, separately, for each individual operator — to open or continue a TAVR program; this newsroom could not independently re-verify the prior numeric thresholds against CMS's own text, so we are not printing exact figures here. The practical effect professional societies describe: an existing cardiac-surgery hospital that previously could not hit the case-volume bar to justify or sustain a TAVR program has a lower administrative barrier to doing so now. A hospital with no cardiac surgery program at all remains excluded.

Coverage with Evidence Development (CED) — the framework that required hospitals to report outcomes into an approved registry, historically the STS/ACC Transcatheter Valve Therapy Registry — is dropped for the population TAVR already serves, symptomatic severe aortic stenosis. It has not disappeared from the policy altogether: CMS simultaneously expanded Medicare coverage of TAVR to asymptomatic severe AS, a population outside the scope of the prior NCD, and that new coverage is itself conditioned on CED-style evidence collection. In place of mandatory named-registry enrollment for the existing population, hospitals now need a continuous quality-improvement process that assesses procedural outcomes and makes programmatic adjustments — a real change in mechanism, though many programs are expected to keep reporting to the same registries voluntarily.

A cautious yes from cardiology's own societies

The American College of Cardiology, the Society of Thoracic Surgeons and the Society for Cardiovascular Angiography and Interventions issued a joint statement crediting CMS for expanding Medicare access to TAVR as supporting evidence has grown, while emphasizing the importance of preserving the quality framework that has underpinned the procedure's track record — support paired with a caution, not an unqualified endorsement. That caution has a history: during the public comment period on the proposed version of this rule, STS was on record specifically concerned that allowing a single interventional cardiologist to perform TAVR without a cardiac surgeon, and dropping CED altogether, could weaken the evidence base and quality oversight that built TAVR's safety record. The final rule addresses part of that by keeping the heart-team requirement and preserving evidence development for the newly covered asymptomatic population; whether STS considers its original concerns about the established, symptomatic population fully resolved is not something this newsroom found stated plainly in any accessible account of the final rule.

What this does and doesn't open up

Industry estimates — from Edwards Lifesciences' own management commentary and at least one sell-side analyst covering the company — have floated roughly 100 to 200 additional TAVR centers opening over time as a result of this change. Those numbers come from parties with a direct commercial stake in TAVR volume growth, not an independent or CMS estimate, and belong in the story as an industry projection rather than a settled fact. The more concretely supported beneficiaries, per the structural changes above, are existing cardiac-surgery hospitals that previously fell short of volume minimums, and programs that have one TAVR-experienced operator on staff rather than a matched interventional-cardiologist-and-surgeon pair.

What a heart program should do now

• Review your program's operator staffing model against the new single-operator standard, and set heart-team criteria for when a second operator is still warranted case by case.
• Confirm your outcomes-reporting plan. A named national registry is no longer a specific coverage condition, but a documented, continuous quality-improvement process is.
• If your program previously fell short of volume minimums, revisit whether starting or expanding TAVR is now administratively viable — on-site cardiac surgery and ICU capability are still required.
• Check with your Medicare Administrative Contractor on claims-processing guidance; NCD finalization does not always mean billing mechanics are synchronized on day one.

Frequently asked questions

Can any hospital now start offering TAVR?

No. On-site cardiac surgery and critical-care/ICU capability remain required under the updated NCD, per multiple professional-society accounts. This change relieves existing qualifying heart programs of prior volume minimums and the two-operator mandate; it does not open TAVR to hospitals without a cardiac surgery program.

Does a cardiac surgeon still need to be involved in every TAVR case?

The heart team must still include at least one cardiologist and one surgeon as named team members, but a single qualified operator — an interventional cardiologist or a cardiac surgeon — may now perform the procedure alone. The heart team can still call for two operators on a given case if it judges that appropriate.

Is TAVR outcomes-registry participation still a coverage requirement?

Mandatory enrollment in a CMS-approved national registry (such as the STS/ACC TVT Registry, the vehicle used under the prior coverage-with-evidence-development requirement) as a specific coverage condition has been replaced with a more general requirement that hospitals maintain a continuous quality-improvement process assessing procedural outcomes. Many programs are expected to keep using existing registries voluntarily.